Clinical Trial Update: A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors [Phase 2]

View source ↗

Summary

Phase II clinical trial evaluating 131I-Metaiodobenzylguanidine (MIBG) for metastatic or unresectable pheochromocytoma and related tumors has completed with pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Paraganglioma
• Pheochromocytoma

Drugs mentioned

• 131I-Metaiodobenzylguanidine (MIBG) (metaiodobenzylguanidine)

Snippet

Sponsor: University of California, San Francisco | Conditions: Pheochromocytoma, Paraganglioma | Phase 2 | Status: COMPLETED | Results posted: 2018-09-18